Adaptive Biotechnologies Corporation
A maker of tools that read the immune system's genetic code. Its FDA-authorized clonoSEQ test hunts for the tiny traces of cancer cells that can linger after treatment for blood cancers like multiple myeloma, helping doctors spot a possible relapse early. The company was founded in 2009 by brothers Harlan and Chad Robins, after Harlan's lab work at a Seattle research center cracked how to sequence T-cell receptors; Chad, a business guy who joked he couldn't tell a T-cell receptor from a T-bone steak, handled the company side.
Granted 3.20M · Sold 2.73M
Granted 2.26M · Sold 920.5K
Granted 790.0K · Sold 258.4K
Granted 379.8K · Sold 101.4K
Granted 1.41M · Sold 1.08M
Granted 1.13M · Sold 936.4K
Granted 469.7K · Sold 215.8K
Granted 609.8K · Sold 379.5K
Granted 248.8K · Sold 10.0K
Granted 198.9K · Sold 81.3K
Granted 162.8K · Sold 42.4K
Granted 203.3K · Sold 79.0K
Granted 83.8K
Granted 68.2K
Granted 136.8K · Sold 76.0K
Granted 21.5K
Granted 21.5K
Granted 44.4K · Sold 44.4K
Sold 5.7K
Granted 183.9K · Sold 169.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Robins Chad MCEO and Chairman, Director · 50 transactions | +27% | 2.18M | 3.20M | — | 2.73M |
| Robins Harlan SChief Scientific Officer · 53 transactions | +1927% | 1.41M | 2.26M | — | 920.5K |
| Peterson TychoChief Financial Officer · 11 transactions | — | 531.6Kas of Mar 2024 | 790.0K | — | 258.4K |
| Bobulsky SusanChief Commercial Officer, MRD · 12 transactions | +4341.7% | 406.8K | 379.8K | — | 101.4K |
| Rubinstein JuliePresident and COO · 107 transactions | +766.7% | 396.8K | 1.41M | — | 1.08M |
| Benzeno SharonChief Commercial Ofc Imm Med · 33 transactions | +1208.3% | 299.5K | 1.13M | — | 936.4K |
| Piskel KyleChief Financial Officer · 30 transactions | — | 256.7K | 469.7K | — | 215.8K |
| Lo FrancisChief People Officer · 36 transactions | +909.5% | 253.4K | 609.8K | — | 379.5K |
| Neupert Peter MDirector · 9 transactions | +15878.4% | 240.3K | 248.8K | — | 10.0K |
| Sood NitinChief Commercial Officer, MRD · 8 transactions | +121% | 214.8Kas of Aug 2023 | 198.9K | — | 81.3K |
| Adams R MarkChief Operating Officer · 17 transactions | +219% | 175.4Kas of Apr 2023 | 162.8K | — | 42.4K |
| Taylor Stacy LSVP and General Counsel · 15 transactions | +625.7% | 139.4Kas of Aug 2024 | 203.3K | — | 79.0K |
| Owen Katey EinterzDirector · 5 transactions | +1886.4% | 88.3K | 83.8K | — | — |
| Pellini Michael JDirector · 4 transactions | +224.1% | 69.7Kas of Mar 2025 | 68.2K | — | — |
| Hershberg RobertDirector · 8 transactions | +3017.4% | 62.3K | 136.8K | — | 76.0K |
| Trigg LeslieDirector · 2 transactions | +483.1% | 25.9Kas of Mar 2023 | 21.5K | — | — |
| Conroy Kevin TDirector · 2 transactions | +1427.1% | 23.0Kas of Mar 2023 | 21.5K | — | — |
| Cohen Chad MChief Financial Officer · 14 transactions | -31.6% | 21.6Kas of Dec 2021 | 44.4K | — | 44.4K |
| Baldo LanceChief Medical Officer · 2 transactions | -25% | 17.2Kas of Mar 2022 | — | — | 5.7K |
| Griffin Michelle ReneeDirector · 13 transactions | +938.9% | 15.6K | 183.9K | — | 169.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -7.13M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.